Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021

Feldman, William B., Tu, S. Sean, Alhiary, Rasha, Kesselheim, Aaron S. and Wouters, Olivier J. ORCID: 0000-0002-2514-476X (2023) Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. JAMA, 329 (1). 87 - 89. ISSN 0098-7484

Text (Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021) - Accepted Version Download (151kB)

• Author
• Scopus publication

Abstract

Inhalers remain the cornerstone therapy for patients with asthma and chronic obstructive pulmonary disease (COPD). Over the past several decades, brand-name manufacturers have continued to sell most inhalers at high prices without the threat of direct generic competition. They have arranged for long periods of market exclusivity by obtaining patents not just on the active ingredients (primary patents) but also on peripheral aspects of these products, such as the propellants and delivery devices (secondary patents), and by shifting active ingredients to different devices (device hops), thereby adding new secondary patents.

Item Type:	Article
Official URL:	https://jamanetwork.com/journals/jama
Additional Information:	© 2023 American Medical Association
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	09 Jan 2023 09:39
Last Modified:	15 Apr 2024 21:33
URI:	http://eprints.lse.ac.uk/id/eprint/117798

Actions (login required)

View Item